The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $32.32 to a high of $330.75 / share. The average price target represents an increase of 61.59% from the latest reported closing price of $51.31 / share.
What is the Fund Sentiment?
There are 621 funds or institutions reporting positions in CRISPR Therapeutics. This is an decrease of 36 owner(s) or 5.48% in the last quarter. Average portfolio weight of all funds dedicated to CRSP is 0.22%, an increase of 2.91%. Total shares owned by institutions decreased in the last three months by 1.04% to 91,602K shares. 
The put/call ratio of CRSP is 0.53, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 9,787K shares representing 10.27% ownership of the company. In its prior filing, the firm reported owning 10,183K shares , representing a decrease of 4.04%. The firm increased its portfolio allocation in CRSP by 3.97% over the last quarter.
ARKK - ARK Innovation ETF holds 7,626K shares representing 8.00% ownership of the company. In its prior filing, the firm reported owning 6,341K shares , representing an increase of 16.85%. The firm increased its portfolio allocation in CRSP by 10.78% over the last quarter.
Capital International Investors holds 5,649K shares representing 5.93% ownership of the company. In its prior filing, the firm reported owning 5,594K shares , representing an increase of 0.98%. The firm increased its portfolio allocation in CRSP by 26.13% over the last quarter.
Orbis Allan Gray holds 4,982K shares representing 5.23% ownership of the company. In its prior filing, the firm reported owning 2,765K shares , representing an increase of 44.51%. The firm increased its portfolio allocation in CRSP by 111.95% over the last quarter.
T. Rowe Price Investment Management holds 3,283K shares representing 3.44% ownership of the company. In its prior filing, the firm reported owning 3,683K shares , representing a decrease of 12.20%. The firm increased its portfolio allocation in CRSP by 14.97% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
